Microbiome Research Centre
Transforming invisible microbes into visible health benefits – personalised medicine for Australians and the world
Learn More
Research Group
86 •
Challenge
Many patients face diseases – including cancer, obesity, dementia, and pregnancy complications – where treatments are often ineffective, poorly targeted, or cause severe side effects.
Doctors lack tools to predict who will benefit, match therapies to individuals, or deliver personalised treatments, leaving patients exposed to unnecessary risks and delayed or suboptimal care.
Solution
The Centre develops innovative approaches to tackle these challenges by creating nextgeneration live microbial therapies, intelligent faecal microbiota transplantation( iFMT) that precisely matches donors to recipients, and microbe-based predictive tools to identify patients most likely to benefit before treatment. These systems can be adopted by clinicians to improve patient care, integrated into existing healthcare pathways, and scaled through partnerships and commercialisation, ensuring sustainable, evidence-based, personalised microbiome-driven therapies for diverse diseases.
Target customers / end-users
• healthcare providers – adopt microbial therapies and predictive tools for personalised care
• patients – benefit from safer, targeted microbiome treatments
• industry and commercial partners – invest, licence, and scale microbiome healthcare innovations globally
Progress
• prototypes developed and evaluated, two patent applications in progress
• collaborating with 100 + research and clinical organisations, nationally and internationally
• 10,000 + patient cohorts, three active industry expressions of interest
100 active collaborations
Multidisciplinary team
Innovative research translation
Healthy Living
The Microbiome Research Centre harnesses the body’ s microbes to develop next-generation therapies, personalised faecal microbiota transplantation, and AI-driven diagnostic tools. Engaging over 100 research and clinical partners and more than 10,000 patient cohorts, its validated prototypes and active industry interest demonstrate real-world impact, improving treatment precision, reducing side effects, and advancing global healthcare.